MAIA Biotech(MAIA.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
MAIA Biotech
MAIA.US
MAIA Biotechnology, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the development of targeted immunotherapies for cancer. Its lead product Ateganosine, a telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC). The company was incorporated in 2018 and is headquartered in Chicago, Illinois.
1.850 T
MAIA.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    MAIA Biotechnology to Terminate ATM Agreement With H.C. Wainwright After Raising $5.68M

    TradingView·
    US
    MAIA
    +4.88%
    US
    IXJ
    +0.35%
    US
    XBI
    +3.88%
    TradingView·
    US
    MAIA
    +4.88%
    US
    IXJ
    +0.35%
    US
    XBI
    +3.88%

    MAIA Biotech | 10-Q: FY2026 Q1 Revenue: USD 0

    Earnings Watch·
    US
    MAIA
    +4.88%
    Earnings Watch·
    US
    MAIA
    +4.88%

    MAIA Biotechnology (MAIA) Projected to Post Quarterly Earnings on Friday

    Market Beat·
    US
    MAIA
    +4.88%
    US
    XBI
    +3.88%
    US
    FBT
    +2.14%
    Market Beat·
    US
    MAIA
    +4.88%
    US
    XBI
    +3.88%
    US
    FBT
    +2.14%

    MAIA Biotechnology activates first U.S. site for THIO-101 Phase 2 expansion, NIH funds $2.3M

    TradingView·
    US
    MAIA
    +4.88%
    US
    SBIO
    +3.75%
    US
    IXJ
    +0.35%
    TradingView·
    US
    MAIA
    +4.88%
    US
    SBIO
    +3.75%
    US
    IXJ
    +0.35%

    MAIA Biotechnology Activates First U.S. Site for Ongoing International Phase 2 Expansion Trial of Novel Telomere Targeting Treatment Targeting Advanced Non-Small Cell Lung Cancer | MAIA Stock News

    StockTitan·
    US
    MAIA
    +4.88%
    StockTitan·
    US
    MAIA
    +4.88%
    © 2026 Longbridge｜Disclaimer